Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Rizzieri

Showing results (61-70 of 132) with videos related to

Pageof 14
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 11, 2017
Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and HospitalizationSarah Anand, Samantha Thomas, Terry Hyslop, et al.
Transplantation and Cellular Therapy|June 19, 2021
Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell TransplantationPrioty Islam, Helen Tang, Haesu Jin, et al.
Cancer Investigation|December 21, 2010
Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donorsDavid A Rizzieri, Christopher Crout, Robert Storms, et al.
Cancer|May 26, 2004
Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphomaDavid A Rizzieri, Gregory J Sand, Dean McGaughey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemiaDavid A Rizzieri, Valerie K Ibom, Joseph O Moore, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 16, 2010
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapseAnjali S Advani, Mazyar Shadman, Francis Ali-Osman, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 6, 2013
Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell functionSharon Lim, Tzuen Yih Saw, Min Zhang, et al.
Blood Advances|March 16, 2021
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analysesTara L Lin, David A Rizzieri, Daniel H Ryan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 22, 2020
Clinical and Neuroimaging Correlates of Post-Transplant DeliriumPatrick Smith, Jillian C Thompson, Elena Perea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 MutationsDaniel A Pollyea, Courtney D DiNardo, Martha L Arellano, et al.
Pageof 14

Showing results (61-70 of 132) with videos related to

Sort By:
Pageof 14
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 11, 2017
Transplantation of Ex Vivo Expanded Umbilical Cord Blood (NiCord) Decreases Early Infection and HospitalizationSarah Anand, Samantha Thomas, Terry Hyslop, et al.
Transplantation and Cellular Therapy|June 19, 2021
Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell TransplantationPrioty Islam, Helen Tang, Haesu Jin, et al.
Cancer Investigation|December 21, 2010
Feasibility of low-dose interleukin-2 therapy following T-cell-depleted nonmyeloablative allogeneic hematopoietic stem cell transplantation from HLA-matched or -mismatched family member donorsDavid A Rizzieri, Christopher Crout, Robert Storms, et al.
Cancer|May 26, 2004
Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphomaDavid A Rizzieri, Gregory J Sand, Dean McGaughey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2003
Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemiaDavid A Rizzieri, Valerie K Ibom, Joseph O Moore, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 16, 2010
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapseAnjali S Advani, Mazyar Shadman, Francis Ali-Osman, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 6, 2013
Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell functionSharon Lim, Tzuen Yih Saw, Min Zhang, et al.
Blood Advances|March 16, 2021
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analysesTara L Lin, David A Rizzieri, Daniel H Ryan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 22, 2020
Clinical and Neuroimaging Correlates of Post-Transplant DeliriumPatrick Smith, Jillian C Thompson, Elena Perea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 20, 2022
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 MutationsDaniel A Pollyea, Courtney D DiNardo, Martha L Arellano, et al.
Pageof 14